Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach.

MLA

Lee, Jong Bong, et al. “Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach.” Journal of Pharmaceutical Sciences, vol. 108, no. 2, Feb. 2019, pp. 1047–52. EBSCOhost, https://doi.org/10.1016/j.xphs.2018.09.025.

APA

Lee, J. B., Kim, T. H., Feng, W., Choi, H. G., Zgair, A., Shin, S., Yoo, S. D., Gershkovich, P., & Shin, B. S. (2019). Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach. Journal of Pharmaceutical Sciences, 108(2), 1047–1052. https://doi.org/10.1016/j.xphs.2018.09.025

Chicago

Lee, Jong Bong, Tae Hwan Kim, Wanshan Feng, Hyeon Gwan Choi, Atheer Zgair, Soyoung Shin, Sun Dong Yoo, Pavel Gershkovich, and Beom Soo Shin. 2019. “Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach.” Journal of Pharmaceutical Sciences 108 (2): 1047–52. doi:10.1016/j.xphs.2018.09.025.